These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22570424)

  • 1. Cardiomyopathy prognosis after benznidazole treatment in chronic canine Chagas' disease.
    Santos FM; Lima WG; Gravel AS; Martins TA; Talvani A; Torres RM; Bahia MT
    J Antimicrob Chemother; 2012 Aug; 67(8):1987-95. PubMed ID: 22570424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.
    Caldas IS; Menezes APJ; Diniz LF; Nascimento ÁFDSD; Novaes RD; Caldas S; Bahia MT
    Acta Trop; 2019 Jan; 189():30-38. PubMed ID: 30290285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chagas cardiomyopathy: The potential effect of benznidazole treatment on diastolic dysfunction and cardiac damage in dogs chronically infected with Trypanosoma cruzi.
    Santos FM; Mazzeti AL; Caldas S; Gonçalves KR; Lima WG; Torres RM; Bahia MT
    Acta Trop; 2016 Sep; 161():44-54. PubMed ID: 27215760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-gamma, TNF-alpha, and low IL-10 production during the acute infection phase.
    Guedes PM; Veloso VM; Afonso LC; Caliari MV; Carneiro CM; Diniz LF; Marques-da-Silva EA; Caldas IS; Do Valle Matta MA; Souza SM; Lana M; Chiari E; Galvão LM; Bahia MT
    Vet Immunol Immunopathol; 2009 Jul; 130(1-2):43-52. PubMed ID: 19211152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study of posaconazole and benznidazole in the prevention of heart damage and promotion of trypanocidal immune response in a murine model of Chagas disease.
    Olivieri BP; Molina JT; de Castro SL; Pereira MC; Calvet CM; Urbina JA; Araújo-Jorge TC
    Int J Antimicrob Agents; 2010 Jul; 36(1):79-83. PubMed ID: 20452188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards the establishment of a consensus real-time qPCR to monitor Trypanosoma cruzi parasitemia in patients with chronic Chagas disease cardiomyopathy: a substudy from the BENEFIT trial.
    Moreira OC; Ramírez JD; Velázquez E; Melo MF; Lima-Ferreira C; Guhl F; Sosa-Estani S; Marin-Neto JA; Morillo CA; Britto C
    Acta Trop; 2013 Jan; 125(1):23-31. PubMed ID: 22982466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
    Cevey ÁC; Mirkin GA; Penas FN; Goren NB
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benznidazole alters the pattern of Cyclophosphamide-induced reactivation in experimental Trypanosoma cruzi-dependent lineage infection.
    Santos DM; Martins TA; Caldas IS; Diniz LF; Machado-Coelho GL; Carneiro CM; Oliveira Rde P; Talvani A; Lana M; Bahia MT
    Acta Trop; 2010 Feb; 113(2):134-8. PubMed ID: 19854145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myocardial scars correlate with eletrocardiographic changes in chronic Trypanosoma cruzi infection for dogs treated with Benznidazole.
    Caldas IS; da Matta Guedes PM; dos Santos FM; de Figueiredo Diniz L; Martins TA; da Silva do Nascimento AF; Azevedo MA; de Lima WG; Neto RM; Torres RM; Talvani A; Bahia MT
    Trop Med Int Health; 2013 Jan; 18(1):75-84. PubMed ID: 23107306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-time PCR strategy for parasite quantification in blood and tissue samples of experimental Trypanosoma cruzi infection.
    Caldas S; Caldas IS; Diniz Lde F; Lima WG; Oliveira Rde P; Cecílio AB; Ribeiro I; Talvani A; Bahia MT
    Acta Trop; 2012 Sep; 123(3):170-7. PubMed ID: 22609548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with benznidazole or thioridazine in the chronic phase of experimental Chagas disease improves cardiopathy.
    Bustamante JM; Presti MS; Rivarola HW; Fernández AR; Enders JE; Fretes RE; Paglini-Oliva P
    Int J Antimicrob Agents; 2007 Jun; 29(6):733-7. PubMed ID: 17395432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of specific treatment on parasitological and histopathological parameters in mice infected with different Trypanosoma cruzi clonal genotypes.
    Toledo MJ; Bahia MT; Veloso VM; Carneiro CM; Machado-Coelho GL; Alves CF; Martins HR; Cruz RE; Tafuri WL; Lana M
    J Antimicrob Chemother; 2004 Jun; 53(6):1045-53. PubMed ID: 15102747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Higher incidence of malignant neoplasms after heart transplantation for treatment of chronic Chagas' heart disease.
    Bocchi EA; Higuchi ML; Vieira ML; Stolf N; Bellotti G; Fiorelli A; Uip D; Jatene A; Pileggi F
    J Heart Lung Transplant; 1998 Apr; 17(4):399-405. PubMed ID: 9588585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT).
    Marin-Neto JA; Rassi A; Morillo CA; Avezum A; Connolly SJ; Sosa-Estani S; Rosas F; Yusuf S;
    Am Heart J; 2008 Jul; 156(1):37-43. PubMed ID: 18585495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
    Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benznidazole prevents endothelial damage in an experimental model of Chagas disease.
    Molina-Berríos A; Campos-Estrada C; Lapier M; Duaso J; Kemmerling U; Galanti N; Leiva M; Ferreira J; López-Muñoz R; Maya JD
    Acta Trop; 2013 Jul; 127(1):6-13. PubMed ID: 23529066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benznidazole treatment in chronic children infected with Trypanosoma cruzi: serological and molecular follow-up of patients and identification of Discrete Typing Units.
    Rumi MM; Pérez Brandán C; Gil JF; D'Amato AM; Ragone PG; Lauthier JJ; Tomasini N; Cimino RO; Orellana V; Lacunza CD; Nasser JR; Basombrío MA; Diosque P
    Acta Trop; 2013 Oct; 128(1):130-6. PubMed ID: 23880286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indeterminate Chagas' disease: Trypanosoma cruzi strain and re-infection are factors involved in the progression of cardiopathy.
    Bustamante JM; Rivarola HW; Fernández AR; Enders JE; Fretes R; Palma JA; Paglini-Oliva PA
    Clin Sci (Lond); 2003 Apr; 104(4):415-20. PubMed ID: 12653687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical aspects of the Chagas' heart disease.
    Punukollu G; Gowda RM; Khan IA; Navarro VS; Vasavada BC
    Int J Cardiol; 2007 Feb; 115(3):279-83. PubMed ID: 16769134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.